Clinical Trials Logo

Clinical Trial Summary

The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study. APLICOV-PC study was a multicenter, randomized, proof-of-concept clinical trial to assess the safety profile of 3 different dose levels of plitidepsin (1,5 mg, 2,0 mg and 2,5 mg) administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital admission.

Clinical Trial Description

The APLICOV-PC proof of concept study demonstrated the antiviral activity of plitidepsin in terms of reducing viral load, inducing recovery, and impact on lymphocyte reconstitution and other inflammatory parameters. A percentage of patients, which varies between 10 and 25%, continue to show symptoms at 3 months after contracting the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: For some of them this significantly restricts their life, requiring them to take long-term sickness leave from work, and leaving them with sequelae that may continue for more than one year. With this study, Pharmamar intends to evaluate whether the treatment with plitidepsin, by attaining a reduction in the viral load and a faster recovery of the patient, could have a relevant impact on the emergence of sequelae resulting from the SARS-CoV-2 infection. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05121740
Study type Interventional
Source PharmaMar
Contact José Jimeno, MD, PhD
Phone + 34 91 846 6036
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date January 2022
Completion date May 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer Phase 2
Active, not recruiting NCT04455815 - A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive. Phase 2
Enrolling by invitation NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Recruiting NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Enrolling by invitation NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Completed NCT04662437 - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Not yet recruiting NCT05123742 - PREDICT: A PBRN Feasibility Study on COVID-19 Screening in Dental Practice
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Recruiting NCT04894266 - An Open-Label Study of Apabetalone in Covid Infection Phase 2/Phase 3
Recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting NCT04387656 - NCI COVID-19 in Cancer Patients, NCCAPS Study
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
Recruiting NCT04382781 - Immunosupressive Treatment in COVID-19 Patients